Core Viewpoint - The stock of Sairis Medical Technology Group Co., Ltd. has experienced an abnormal trading fluctuation, with a cumulative closing price increase of over 20% in three consecutive trading days, prompting the company to issue a notice regarding this situation [2][3]. Group 1: Stock Trading Abnormality - The company's stock price has deviated significantly, with a cumulative increase of over 20% in three consecutive trading days, which is classified as an abnormal trading fluctuation according to the Shanghai Stock Exchange rules [2][3]. - The company has conducted a self-examination and confirmed that its production and operational activities are normal, with no significant changes in the market environment or industry policies [4]. Group 2: Verification of Major Events - The company has verified with its controlling shareholder, Saihai (Shanghai) Health Technology Co., Ltd., and its actual controller, Mr. Wen Wei, that there are no undisclosed major events that could affect the stock price, including major asset restructuring, share issuance, or significant business cooperation [4]. - There have been no significant media reports or market rumors that could impact the company's stock price, and no other sensitive information has been identified that could affect the stock [5][6]. Group 3: Board of Directors' Statement - The board of directors confirms that there are no undisclosed matters that should be reported according to the Shanghai Stock Exchange rules, and all previously disclosed information is accurate without the need for correction or supplementation [10].

Core Viewpoint - The company, Sely Medical, announced that its stock price has deviated significantly, with a cumulative increase of over 20% in the last three trading days, indicating abnormal trading fluctuations [1] Company Operations - The company conducted a self-examination and confirmed that all production and operational activities are normal [1] - There have been no significant changes in the market environment or industry policies affecting the company [1] - The internal production and operational order remains normal [1] Disclosure of Information - The company stated that there are no major events that could impact the abnormal fluctuations in stock trading prices [1] - There are no undisclosed significant information that should have been disclosed [1]

| 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-071 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 塞力斯医疗科技集团股份有限公司（以下简称"公司"）股票连续3个交 易日内日收盘价格涨幅偏离值累计超过20%，根据《上海证券交易所交易规则》 的有关规定，属于股票交易异常波动情形。 经公司自查，并向控股股东赛海（上海）健康科技有限公司（以下简称 "赛海科技"）及实际控制人温伟先生发函核实，截至本公告披露日，控股股东 及实际控制人不存在应披露而未披露的重大信息，包括但不限于重大资产重组、 股份发行、重大交易类事项、业务重组、股份回购、破产重整、重大业务合作、 引进战略投资者等重大事项。 风险提示详见本公告"三、相关风险提示"，公司倡导价值投资并专注 于主业的发展，敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 一、股票交 ...

Market Overview - The Shanghai Composite Index fell by 0.39% on August 26, with 17 sectors rising, led by Agriculture, Forestry, Animal Husbandry, and Fishery (up 2.62%) and Beauty and Personal Care (up 2.04%) [1] - The sectors that experienced the largest declines were Pharmaceutical and Biological (down 1.09%) and Non-Bank Financials (down 1.06%) [1] - Overall, there was a net outflow of 68.855 billion yuan in the main funds across the two markets, with only two sectors seeing net inflows: Beauty and Personal Care (net inflow of 276 million yuan) and Agriculture, Forestry, Animal Husbandry, and Fishery (net inflow of 257 million yuan) [1] Pharmaceutical and Biological Sector - The Pharmaceutical and Biological sector saw a decline of 1.09%, with a net outflow of 8.254 billion yuan in main funds [2] - Out of 474 stocks in this sector, 151 stocks rose, 3 stocks hit the daily limit, and 307 stocks fell [2] - The stocks with the highest net inflows included Kangdelai (net inflow of 112 million yuan), Wanbangde (net inflow of 111 million yuan), and Anke Bio (net inflow of 80.217 million yuan) [2] - The stocks with the largest net outflows included Hanyu Pharmaceutical (net outflow of 766 million yuan), WuXi AppTec (net outflow of 706 million yuan), and Sihai Medical (net outflow of 408 million yuan) [2] Fund Flow Analysis Inflow Leaders - Kangdelai: +10.05% with a turnover rate of 10.15% and main fund flow of 111.545 million yuan [3] - Wanbangde: +9.97% with a turnover rate of 8.58% and main fund flow of 110.956 million yuan [3] - Anke Bio: -0.25% with a turnover rate of 9.03% and main fund flow of 80.217 million yuan [3] Outflow Leaders - Hanyu Pharmaceutical: -5.94% with a turnover rate of 16.12% and main fund flow of -766.138 million yuan [4] - WuXi AppTec: -3.18% with a turnover rate of 2.70% and main fund flow of -705.940 million yuan [4] - Sihai Medical: +4.99% with a turnover rate of 37.04% and main fund flow of -407.547 million yuan [4]

Group 1 - The stock of Saily Medical (603716) increased by 4.99% with a turnover rate of 37.04% and a trading volume of 2.592 billion yuan, showing a volatility of 10.17% [2] - The stock was listed on the Shanghai Stock Exchange's daily trading list due to a turnover rate of 33.66%, with a net buying amount of 146 million yuan from brokerage seats [2] - In the last six months, the stock has appeared on the trading list 32 times, with an average price increase of 2.06% the next day and an average increase of 7.23% over five days after being listed [2] Group 2 - The company reported a first-quarter revenue of 287 million yuan, a year-on-year decrease of 40.75%, and a net loss of 14.32 million yuan [2] - On July 15, the company released a half-year performance forecast, expecting a net loss between 66 million yuan and 55 million yuan, representing a year-on-year change of -1282.92% to -1052.44% [3] - The top five buying and selling brokerage seats on August 26 included Guotai Junan Securities Headquarters, CITIC Securities Shanghai Branch, and UBS Securities, with significant buying and selling amounts [3][4]

塞力医疗(603716.SH)公告称，公司股票连续3个交易日内日收盘价格涨幅偏离值累计超过20%，属于股 票交易异常波动情形。经核实，公司生产经营活动一切正常，市场环境、行业政策没有发生重大调整， 内部生产经营秩序正常。控股股东及实际控制人不存在应披露而未披露的重大信息。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Group 1 - The SPD sector of the medical consumables supply chain saw a slight increase of 0.05% on August 26, with Kangdelai leading the gains [1] - The Shanghai Composite Index closed at 3868.38, down 0.39%, while the Shenzhen Component Index closed at 12473.17, up 0.26% [1] - Kangdelai's stock price rose by 10.05% to 9.64, with a trading volume of 443,300 shares and a transaction value of 425 million yuan [1] Group 2 - The SPD sector experienced a net outflow of 407 million yuan from main funds, while retail investors saw a net inflow of 408 million yuan [2] - The trading data indicates that Kangdelai had a net inflow of 101 million yuan from main funds, despite a net outflow from speculative funds [3] - Other notable stocks included Langma Information and Dashi Intelligent, which also experienced varying degrees of net inflow and outflow from different investor types [3]

Market Overview - The pharmaceutical commercial sector rose by 0.12% on August 26, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3868.38, down by 0.39%, while the Shenzhen Component Index closed at 12473.17, up by 0.26% [1] Stock Performance - Saily Medical (603716) closed at 36.40, up by 4.99% with a trading volume of 707,500 shares and a transaction value of 2.592 billion [1] - Baiyang Pharmaceutical (301015) closed at 25.78, up by 2.14% with a trading volume of 96,000 shares and a transaction value of 247 million [1] - Other notable performers include: - People's Tongtai (600829) at 8.47, up by 1.68% [1] - Luyuan Pharmaceutical (002788) at 8.85, up by 0.91% [1] - Yiyigou (300937) at 30.17, up by 0.90% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 502 million from institutional investors, while retail investors saw a net inflow of 453 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - People's Tongtai (600829) had a net inflow of 24.93 million from institutional investors, but a net outflow of 28.53 million from retail investors [3] - Baiyang Pharmaceutical (301015) saw a net inflow of 16.19 million from institutional investors, with retail investors withdrawing 14.69 million [3] - Other stocks with significant capital movements include: - Swiss Pharmaceutical (002589) with a net inflow of 14.79 million from institutional investors [3] - National Pharmaceutical (600511) with a net inflow of 11.70 million from institutional investors [3]

Market Overview - The pharmaceutical commercial sector increased by 0.76% on August 25, with Saily Medical leading the gains [1] - The Shanghai Composite Index closed at 3883.56, up 1.51%, while the Shenzhen Component Index closed at 12441.07, up 2.26% [1] Stock Performance - Saily Medical (603716) closed at 34.67, up 9.99% with a trading volume of 451,800 shares and a transaction value of 1.537 billion [1] - Run Da Medical (603108) closed at 18.90, up 3.00% with a trading volume of 482,200 shares [1] - First Medical (600833) closed at 13.51, up 2.82% with a trading volume of 125,700 shares [1] - Other notable performers include Haiwang Biological (000078) up 2.60% and Shanghai Pharmaceutical (601607) up 1.94% [1] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 136 million from institutional investors, while retail investors experienced a net inflow of 12.65 million [2] - The sector had a net outflow of 148 million from speculative funds [2] Individual Stock Capital Flow - Saily Medical had a net inflow of 1.87 billion from institutional investors, but a net outflow of 1.18 billion from speculative funds [3] - Shanghai Pharmaceutical saw a net inflow of 27.34 million from institutional investors, with a net outflow of 30.82 million from speculative funds [3] - First Medical had a net inflow of 24.77 million from institutional investors, while experiencing a net outflow of 7.56 million from speculative funds [3]

天眼查商业履历信息显示，塞力斯医疗科技集团股份有限公司，成立于2004年，位于武汉市，是一家以 从事研究和试验发展为主的企业。企业注册资本19095.2305万人民币，实缴资本3800万人民币。公司法 定代表人为温伟。 金融界消息 截至2025年8月25日收盘，塞力医疗（603716）报收于34.67元，上涨9.99%，换手率 23.65%，成交量45.18万手，成交金额15.37亿元。 资金流向方面，今日主力资金净流入1.87亿元，占比成交额12.17%。其中，超大单净流入2.74亿元、占 成交额17.85%，大单净流出8742.93万元、占成交额5.69%，中单净流出流出11779.00万元、占成交额 7.66%，小单净流出6917.30万元、占成交额4.5%。 塞力医疗最新一期业绩显示，截至2025一季报，公司营业总收入2.87亿元、同比减少40.75%，归属净利 润1432.09万元，同比减少553.66%，扣非净利润2846.33万元，同比减少3228.81%，流动比率1.931、速 动比率1.591、资产负债率58.57%。 通过天眼查大数据分析，塞力斯医疗科技集团股份有限公司共对外投资了70家企 ...